Pericardial disease in patients treated with immune checkpoint inhibitors
| Autor: | Anju Nohria, Vineet K Raghu, Jingyi Gong, Ryan Sullivan, Leyre Zubiri, Tomas G Neilan, Amna Zafar, Raza M Alvi, Sarah Hartmann, Hannah K Gilman, Meghan E Sise, Zsofia Dora Drobni, Thiago Quinaglia, Carlos Gongora, Daniel Zlotoff |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2021-0027 2051-1426 |
| DOI: | 10.1136/jitc-2021-002771 |
| Popis: | Background There are limited data on the occurrence, associations and outcomes of pericardial effusions and pericarditis on or after treatment with immune checkpoint inhibitors (ICIs).Methods This was a retrospective study at a single academic center that compared 2842 consecutive patients who received ICIs with 2699 age- and cancer-type matched patients with metastatic disease who did not receive ICI. A pericardial event was defined as a composite outcome of pericarditis and new or worsening moderate or large pericardial effusion. The endpoints were obtained through chart review and were blindly adjudicated. To identify risk factors associated with a pericardial event, we compared patients who developed an event on an ICI with patients treated with an ICI who did not develop a pericardial event. Cox proportional-hazard model and logistical regression analysis were performed to study the association between ICI use and pericardial disease as well as pericardial disease and mortality. An additional 6-week landmark analysis was performed to account for lead-time bias.Results There were 42 pericardial events in the patients treated with ICI (n=2842) over 193 days (IQR: 64–411), yielding an incidence rate of 1.57 events per 100 person-years. There was a more than fourfold increase in risk of pericarditis or a pericardial effusion among patients on an ICI compared with controls not treated with ICI after adjusting for potential confounders (HR 4.37, 95% CI 2.09 to 9.14, p0.7 mg/kg prednisone) was associated with increased risk of pericardial disease (HR 2.56, 95% CI 1.00 to 6.57, p=0.049).Conclusions ICI use was associated with an increased risk of development of pericardial disease among patients with cancer and a pericardial event on an ICI was associated with a trend towards increase in mortality. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|